DailyIQ
|
Sector:HealthcareAll sectors
Last updated 4 minutes ago

DXCM·DexCom, Inc.

$.
-. (-.%)
After Hours
High
$72.65
Open
$72.53
Market Cap
27.99B
52W High
$89.98
Low
$69.92
P. Close
$70.24
P/E
30.09
52W Low
$54.11
Fwd P/E
118.35
Mean Target
$81.64
Technical Score (1D)
59
BUY
News Sentiment
55
BULLISH
DexCom's investment narrative is shifting as analysts adjust valuation models, with fair value estimates now anchored around $81.64. Following recent Investor Day updates, some firms have trimmed price targets, reflecting a balance between confidence in execution and more cautious long-term growth assumptions. Despite these adjustments, Buy ratings persist, underpinned by management's financial targets and a strong product pipeline. In a separate development, CEO Kevin Sayer sold 26,759 shares for approximately $1.93 million, though this was executed under a pre-scheduled Rule 10b5-1 trading plan, and he retains substantial ownership. Investors will be watching for continued progress on financial targets and product innovation to support the current Buy ratings.
Earnings Summary
DexCom, Inc. is a prominent medical technology company focused on developing and manufacturing continuous glucose monitoring (CGM) systems for individuals managing diabetes. Operating within the healthcare sector, specifically the medical devices industry, DexCom's core business centers on its advanced CGM devices, designed to provide real-time glucose data, thereby enhancing diabetes management for patients and healthcare providers. The company's product portfolio includes the Dexcom G6 and G7 systems, alongside newer offerings like Dexcom ONE and Stelo, aimed at expanding market reach and accessibility. In its most recent reported quarters, DexCom demonstrated a mixed performance in earnings per share (EPS) against analyst expectations, missing estimates in Q4 2024 (actual $0.45 vs. estimate $0.49928) and Q1 2025 (actual $0.32 vs. estimate $0.32841), but subsequently beating estimates in Q2 2025 (actual $0.48 vs. estimate $0.44341) and Q3 2025 (actual $0.61 vs. estimate $0.56739), and significantly exceeding expectations in Q4 2025 (actual $0.68 vs. estimate $0.47624). Revenue trends, where available, showed growth, with Q4 2025 revenue at $1.26 billion and Q1 2026 revenue at $1.19 billion, though Q1 2026 revenue growth decelerated compared to the prior year. Historically, DexCom has shown a strong revenue growth trajectory, often exceeding analyst revenue estimates when available, though EPS performance has been more variable, with a pattern of beating estimates in the latter half of the provided data set (Q2 2025, Q3 2025, Q4 2025) after missing in the earlier quarters. Recent news highlights several key developments, including the launch of the Dexcom Flex CGM system in Germany to target Type 2 diabetes patients, expanding its market reach beyond intensive insulin therapy users. However, the company is also investigating an incident involving stolen G7 sensor lots, which could lead to increased regulatory scrutiny. Furthermore, DexCom made a strategic $75 million investment in ŌURA, a smart ring maker, to integrate CGM data with wellness metrics, potentially enhancing its value proposition. Investors will be watching for the company's response to the stolen sensor incident and its impact on operations and regulatory standing, as well as the progress of the ŌURA partnership and the market reception of the Dexcom Flex system in new patient segments.

EPS

EstBeatMiss
$0.27$0.38$0.50$0.62$0.73Q1'25Q2'25Q3'25Q4'25Q1'26Q2'26
QtrEstActual+/−
Q2'26$0.61 - -
Q1'26$0.47$0.56+19.0%
Q4'25$0.48$0.68+42.8%
Q3'25$0.57$0.61+7.5%
Q2'25$0.44$0.48+8.3%
Q1'25$0.33$0.32-2.6%

Revenue

EstBeatMiss
$994M$1.1B$1.2B$1.3B$1.4BQ1'25Q2'25Q3'25Q4'25Q1'26Q2'26
QtrEstActual+/−
Q2'26$1.3B - -
Q1'26$1.2B$1.2B+1.5%
Q4'25$1.2B$1.3B+6.5%
Q3'25 - $1.2B -
Q2'25 - $1.2B -
Q1'25 - $1.0B -
Full Earnings BreakdownEstimates, actuals, guidance, and historical context
→

Market Data

DXCM Stock Snapshot

DXCM is currently trading at $70.26, giving DexCom, Inc. a market cap of 27.99B and a P/E ratio of 30.1. Today's range spans $69.92–$72.65, with shares opening at $72.53 and moving up $0.02 (0.0%) from the prior close. DailyIQ's technical score sits at 59/100 (HOLD) with a news sentiment reading of 55/100.

Over the past year DXCM has traded between $54.11 and $89.98 - the current price is +29.8% off the 52-week low and -21.9% from the high. 38 analysts cover the stock with a Buy consensus and a mean 12-month target of $81.64 (range $64.00–$112.00), implying upside of +16.2%.

DexCom, Inc. (DXCM) is a large-cap in Healthcare with 27.99B in market cap, currently sitting on a HOLD signal at 59/100. Price: $70.26 (in the middle of its 52-week range). Sentiment: neutral at 55/100. The current P/E ratio stands at 30.1. The 52-week range of $54.11–$89.98 is the structural anchor, and the current neutral phase is the market's way of asking for more information before committing to a direction.

The 52-week range of $54.11–$89.98 for DXCM provides the structural reference that options traders, systematic funds, and discretionary managers all anchor to — and at $70.26 (in the middle of its 52-week range), the stock sits in a zone where the next 5–10% move will likely define which crowd was right. A HOLD signal at 59/100 and neutral news backdrop (55/100) don't break the tie yet, but they narrow the probability distribution toward the upside.